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Introduction: Malignant pleural mesothelioma (MPM) is an ag-
gressive malignancy arising from mesothelial cells lining the pleura.
Most commonly, it presents as a unilateral pleural effusion. MPM
usually develops on the parietal pleural surface and later spreads to
the visceral pleura. Visceral pleural involvement entails a more
advanced disease stage and is therefore an important prognostic
factor. Pleural fluid (PF) cytology is often the first diagnostic test,
but the sensitivity in the literature varies from 4 to 77%. However,
no data are available for the diagnostic yield of cytological PF
analysis with regard to the visceral pleural involvement. The aim of
this study is to assess whether PF cytological yield is related to the
extent and pattern of visceral pleural invasion, as assessed by
thoracoscopy.
Methods: Medical records of all patients who underwent thoracos-
copy for suspicion of malignant pleural effusion from two hospitals
were reviewed. Patients were selected if they initially underwent a
diagnostic thoracentesis before thoracoscopy, if visceral pleural
appearance during thoracoscopy was clearly documented, and MPM
confirmed on pleural tissue biopsy.
Results: Seventy-five patients were selected. Forty-five patients had
a positive PF cytology on thoracentesis, while 30 had a negative PF
cytology. Thoracoscopy showed parietal pleural invasion in all
subjects. Interestingly, 82% of patients with positive PF cytology on
thoracentesis had visceral pleural involvement, whereas only 30% of
those with negative PF cytology had visceral pleural invasion. The
pattern of visceral pleural invasion consisted of pleural masses,
nodules, or pleural thickening. A multivariate regression identified
visceral pleural invasion (p  0.001) as the only independent factor
predicting the positivity of cytology on pleural effusion.
Conclusion: In epithelioid MPM, PF cytological yield was signif-
icantly higher in patients with visceral pleural invasion assessed by
thoracoscopy. Positive PF cytology is associated with a more ad-
vanced disease.
Key Words: Pleural mesothelioma, Pleural fluid cytology, Thora-
coscopy, Malignant pleural effusion.
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Malignant pleural mesothelioma (MPM) is an aggressivemalignancy with high mortality arising from mesothe-
lial cells lining the pleural cavity.1 The incidence of MPM is
increasing and the diagnosis and therapeutic strategy still
remain difficult. However, diagnosis and treatment at an early
stage of disease improve patients’ survival.2,3 MPM usually
develops on the parietal pleural surface and later spreads to
the visceral pleura. Visceral pleural involvement implies a
more advanced disease stage and is therefore an important
prognostic factor.4
Patients with MPM frequently present with unilateral
pleural effusion so that cytological examination of the effu-
sion fluid can provide the first diagnostic test, which is safe,
simple, and fast.5 The sensitivity of cytological examination
for the diagnosis of MPM reported in the literature varies
widely from 4 to 77%. The reasons for this wide variation are
not clear but have been explained by the difference in sample
size, experience of the cytologist, and the cytological sample
used in different studies.6 An additional factor that may
determine the likelihood of positive cytology is the extent of
the disease. No data are available with regard to the associ-
ation of pleural fluid (PF) cytological yield with visceral
pleural involvement. The aim of this study is to assess
whether PF cytological yield is related to the extent and
pattern of visceral pleural invasion, as assessed by thoracos-
copy.
MATERIALS AND METHODS
Medical records of 103 patients who underwent thora-
coscopy for suspicion of MPM between December 2003 and
January 2009 in two hospitals, in Brescia (Division of Pul-
monology, Spedali Civili, Italy) and Marseille (Division of
Thoracic Oncology, Pleural Diseases, and Interventional Pul-
monology, Hopital Nord, France), were reviewed, with 75
cases fitting for inclusion criteria.
Patients were included if they initially had a diagnostic
thoracentesis before thoracoscopy, if visceral pleural appear-
ance during thoracoscopy was clearly documented, if the
diagnosis of mesothelioma was confirmed in all cases on the
biopsy material, and if the histological type was epithelioid.
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Sarcomatous, mixed, and desmoplastic mesothelioma types
were not included.
Cytology
Cytological material was routinely stained with hema-
toxylin-eosin, Papanicolaou, and Giemsa methods. The cyto-
logical diagnosis was made by an expert cytopathologist in
both centers and findings were reported as follows: (1)
specimens were called cytologically negative if there was no
increase in the number of mesothelial cells and no mesothe-
lial cell atypia; (2) a positive cytological diagnosis was
rendered in the cases that showed marked hypercellularity
and significant mesothelial cell atypia with enlargement of
the cell, nuclei, and nucleoli. Specimens defined as cytolog-
ically atypical or suspicious for mesothelioma were excluded
from this analysis.7,8
Thoracoscopy
Thoracoscopy was standardized in accordance with
current European practice previously described.9 Briefly, tho-
racoscopy was carried out in the lateral decubitus position
under local anesthesia with 1% lidocaine and analgesia and
sedation using propofol or general anesthesia after tracheal
intubation with patient in spontaneous breathing.
A 8-mm Trocar was inserted with or without ultrasono-
graphic guidance in the appropriate intercostal space. A 0°
telescope was inserted and connected to a video camera. The
visceral and parietal pleura were carefully inspected through
the thoracoscope (R. Wolf GmbH, Knittlingen, Germany).9
The appearance of the parietal and visceral pleural
surfaces and the extent of their involvement were assessed
visually by thoracoscopy. The pattern of pleural invasion was
defined as pleural masses, nodules, pleural thickening, and
multiple lesions. Multiple biopsies were taken from parietal
pleura for the histological diagnosis.
Statistical Analysis
A multivariate linear regression analysis was used to
determine independent factors predicting the positivity of
pleural effusion in MPM using SPSS 15.0 statistical software
(SPSS Inc., Chicago, IL). A p value 0.05 was considered
statistically significant.
RESULTS
Seventy-five patients were enrolled in this study. The
age of the patients ranged from 43 to 85 years (mean SD
68 9.07), including 51 men and 24 women. All patients had
a pleural effusion at the time of the first chest radiograph. The
final histological diagnosis of MPM was epithelioid type in
all cases.
Forty-five patients had positive PF cytology after tho-
racentesis (group A), while 30 had negative PF cytology
(group B). No statistically significant differences were found
in age and gender between the two groups.
Thoracoscopy showed parietal pleural invasion in all
subjects. Eighty-two percent of patients with positive PF
cytology had visceral pleural invasion, while only 30% of
those with negative PF cytology had visceral pleural invasion
(Figure 1A). Data are summarized in Table 1.
The endoscopic patterns of pleural invasion were di-
vided as follows: 9% masses, 57% nodules, 9% thickening,
and 25% multiple lesions in group A; 7% masses, 50%
nodules, 20% thickening, and 23% multiple lesions in group
B (Figure 1B).
Multivariate regression analysis identified visceral
pleural invasion (p  0.001) as the only independent factor
predicting the positivity of cytology on pleural effusion,
whereas the different endoscopic lesions (masses, nodules,
thickening, and multiple lesions) did not (Table 2).
Cytological diagnosis in the group of patients with
visceral pleural invasion showed a diagnostic yield of 80.4%
compared with the group of patients without visceral pleural
invasion, which showed a diagnostic yield of 30%.
Twenty-eight patients were excluded from the analysis.
Eight did not receive thoracentesis before thoracoscopy, eight
present pleural adhesions with limitation of visceral pleural
exploration, four have specimens defined as cytologically
suspicious for mesothelioma, four have sarcomatous, three
mixed, and one desmoplastic types.
FIGURE 1. Distribution of visceral pleural involvement (A)
and endoscopic lesions (B) in MPM depending on the pleu-
ral fluid cytology. VPL, presence of visceral pleural inva-
sion; VPL, absence of visceral pleural invasion.
TABLE 1. Results of Cytolologic Analysis of Pleural Fluid
and Visceral Pleural Involvement Assessed by Thoracoscopy
in Patients with MPM
Visceral Pleural
Involvement
 
Cytology positive 37 (82%) 8 (18%)
Cytology negative 9 (30%) 21 (70%)
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DISCUSSION
MPM is a relatively rare tumor, with a growing inci-
dence over the last decades and expected to peak between
2010 and 2020.
It is a primary malignant tumor of the pleural cavity
which develops on the parietal pleura surface and later
spreads to the visceral pleura. Visceral pleura involvement
entails a more advanced stage and is therefore an important
prognostic factor.10 Although MPM is considered an uncom-
mon cause of malignant pleural effusion, patients with MPM
have frequently a pleural effusion as a first symptom.4 There-
fore, cytological evaluation of the PF is the first diagnostic
step in the diagnosis of MPM and is important for early
detection and management of this malignancy.
The sensitivity of cytological examination for the diag-
nosis of MPM ranges from 4 to 77%, and the reasons for this
wide variation are not clear. So far, these differences have
been explained by the discrepancy in sample size, the differ-
ence in term of laboratory techniques, preparation of the
sample, and the cytologist expertise.6,10 To our knowledge,
data are not available with regard to the association of PF
cytological yield and visceral pleural invasion in patients
with MPM.
In this study, we have assessed whether visceral pleural
involvement and endoscopic appearance of MPM may play a
role in the diagnostic yield of PF cytology and whether PF
cytology can predict the visceral pleura involvement and
consequently be considered as a procedure relevant to predict
the prognosis.
To reduce confounding factors, we excluded patients
with suspicious PF cytology. In fact in some specimens with
mild nuclear enlargement, mild increase in the nuclear/cyto-
plasmatic ratio and slight enlarged nucleoli, a definitive
distinction from malignant to reactive mesothelial cells, could
be difficult and depends on the cytologist expertise.
Our data show that 82% of patients with positive PF
cytology had visceral pleural invasion, while only 30% of
those with negative PF cytology had visceral pleural inva-
sion. Multivariate analysis defined visceral pleural invasion
(p  0.001) as an independent factor predicting the positivity
of cytology on pleural effusion. Conversely, the endoscopic
pattern of pleural invasion (masses, nodules, thickening, and
multiple lesions) was not found to play a role in the cytolog-
ical yield of thoracentesis for these patients.
Our results show that in the group of patients with
endoscopic invasion of visceral pleura as assessed by thora-
coscopy, the sensitivity of cytology on pleural effusion is
84.1%, whereas in the group of patients without visceral
pleural invasion, the sensitivity of the cytological evaluation
decreased to 30%. A sensitivity of 84.1% in the cytological
diagnosis of MPM is relevant. Although in the literature some
authors have reported a significantly high degree of sensitiv-
ity (75–90%),11,12 other authors have reported a markedly
lower degree of sensitivity (10%) and some have even
questioned the value of cytology for the diagnosis of MPM.13
Recently, Rakha et al. have published data on 234 cases of
malignant mesothelioma showing that cytological examina-
tion of pleural effusion leads or contributes to the diagnosis in
approximately half of the cases, epithelioid mesothelioma
providing the highest sensitivity in comparison to the sarco-
matoid type. These data confirm the important role of cyto-
logical examination of the PF for the diagnosis of MPM.14
The cytological evaluation of PF seems to influence the
median time related to the diagnosis of MPM. In 1997,
Renshaw et al. published a study trying to define the role of
cytological examination of PF to facilitate early diagnosis.
The sensitivity of cytological examination was 32%, but
interestingly the authors showed that in patients with positive
or suspect cytological results, the median time from initial
symptoms to the diagnosis of MPM was lower than in the
group of patients with negative cytological examination.
Positive or suspect cytological results after thoracentesis has
been shown to shorten the median time of the delay for the
diagnosis.15
Staging of MPM describing the anatomical extent of
the tumor and visceral pleural involvement is crucial in
establishing the stage (tumor node metastasis). The American
Joint Committee on Cancer (AJCC) defines T1 as a tumor
limited to ipsilateral parietal pleura with or without medi-
astinal or diaphragmatic pleural involvement. T1a MPM
represents a disease located to the parietal pleura with no
involvement of the visceral pleura in comparison to T1b
when the tumor involves the visceral pleura.16 It was shown
that the prognosis was related to the extent of visceral pleura
involvement.17,18
In conclusion, our results demonstrate that in MPM PF
cytological yield is significantly higher in patients with vis-
ceral pleural invasion, assuming that the cytology of the
pleural effusion is correlated with mesothelioma extension.
Positive PF cytology might therefore be associated with more
advanced disease.
On the basis of these results in patients with pleural
effusion and high suspicion of MPM, cytological examina-
tion of pleural effusion remains an important diagnostic step,
but even if negative, the recommendation is to perform
thoracoscopy to detect the disease at an early stage.
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